Skip to main content
ATRAptarGroup, Inc.Sell5.0·$128.30-1.56%

AptarGroup (ATR) Q2 2026 earnings — TrendMatrix coverage

BEAT+4.8% vs estimateEPS $1.42 vs $1.35 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$1.42
Estimate
$1.35
Surprise
+4.8%
Score at report (before → after)
5.55.6/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

AptarGroup (ATR) beat the $1.35 estimate with diluted EPS of $1.42 — a clear 4.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.5/10) to Hold at 5.6/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates ATR Sell at 5.0/10.

4 of the last 4 quarters beat the estimate; this quarter's +4.8% surprise compares with a +3.3% four-quarter average. Next scheduled report: 2026-10-29.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Strong earnings beat streak (4/4)

What argues against it

  • Concentration risk — Supplier: single-source resins and rubber components
  • V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
  • Weak overall score: 5.0/10

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$128.30
Price target
$148.02
Stop
$123.49
Upside to target
+15.4%
Reward-to-risk
3.1:1

At 23.5× trailing and 20.3× forward earnings, consensus estimates imply little change in earnings power.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

ATR at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Medical Instruments & Supplies
Market cap
$8.16B
P/E (fwd)
20.3
P/E (ttm)
23.5
52-week range
$103.23$146.91
Off 52-week high
12.7%
RSI (14)
33
Volume vs avg
0.88×
Score today
5.0/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks ATR Earnings Q2 2026 earnings